Biomarkers in community-acquired pneumonia: a state-of-the-art review
- PMID: 23184211
- PMCID: PMC3488993
- DOI: 10.6061/clinics/2012(11)17
Biomarkers in community-acquired pneumonia: a state-of-the-art review
Abstract
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide), adrenomedullin, cortisol and D-dimers.
Conflict of interest statement
No potential conflict of interest was reported.
References
-
- National Center for Health Statistics. Health Statistics. 2006
-
- Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128(4):2238–46. - PubMed
-
- Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med. 2004;32(12):2398–402. - PubMed
-
- Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia.Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest. 1994;105(5):1487–95. - PubMed
-
- Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect. 1985;10(3):204–10. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
